Skip to main content

Table 5 Overall and by components 12-weeks costs expressed in year 2006 Euros.

From: A Cost-Consequences analysis of the effect of Pregabalin in the treatment of peripheral Neuropathic Pain in routine medical practice in Primary Care settings

Costs (€) Non-PGB
(N = 157)
PGB monotherapy
(N = 577)
PGB add-on
(N = 575)
p between groups
  Baseline Change Baseline Change Baseline Change Baseline Change§
Pharmacological treatment 66.8 (93.1) +34.6 (80.3)* 82.3 (106.9) +160.7 (123.9)* 96.8 (120.2) +154.5 (133.0)* 0.004 <0.001
Non-pharmacological treatment 258.8 (1211.6) -191.1 (1,185.5) 168.5 (525.9) -121.9 (494.2)* 290.9 (983.1) -223.6 (948.8)* 0.043 0.220
Medical visits and hospitalizations 430.3 (702.8) -177.0 (695.3) 351.3 (572.6) -203 (485.4)* 497.5 (1,044.6) -250.2 (879.8)* 0.010 0.058
Complementary tests 228.2 (257.0) -104.3 (282.4)* 231.5 (247.2) -158.1 (250.4)* 282.1 (254.9) -173.4 (261.1)* 0.001 0.001
Total direct costs 984.1 (1,684.3) -437.8 (1,582.6) 833.6 (934.4) -322.4 (812.9)* 1,167.3 (1,666.4) -492.7 (1,491.4)* 0.001 0.019
Indirect costs (LWDE) 1,412.5 (1,339.7) -607.5 (1,141.1)* 1,636.1 (1,382.9) -990.5 (1,187.9)* 1,942.2 (1,485.4) -1,072.8 (1,211.7)* <0.001 0.005
Total costs 2,396.6 (2,308.0) -1,045.3 (1,989.6) 2,469.7 (1,856.8) -1,312.9 (1,543.0)* 3,109.5 (2,495.8) -1,565.5 (2,004.1)* <0.001 0.030
  1. Values expressed as means (Standard deviation). *p < 0.0001; p < 0.001; p < 0.05 vs. intragroup baseline values; LWDE = Lost-workdays equivalents. §Between groups changes comparison adjusted by baseline values and number of previous drugs.
\